EGFR and non-small cell lung carcinoma: This correlation weakened the sensitivity of 5-fluorouracil [19] Pemetrexed, another anti-metabolite drug, has also been suggested to have limited efficacy in patients with EGFR mutations [20] Some retrospective studies have reported limited benefits of adjuvant therapy with UFT in patients with EGFR mutation-positive NSCLC [13,18] To our knowledge, this study is the first to examine the effect of UFT based on the EGFR mutation status in a large-scale population.